Objective-The liver is one of the critical organs for lipoprotein metabolism and a major source for phospholipid transfer protein (PLTP) expression. The effect of liver-specific PLTP deficiency on plasma lipoprotein production and metabolism in mice was investigated. Approach and Results-We created a liver-specific PLTP-deficient mouse model. We measured plasma high-density lipoprotein (HDL) and apolipoprotein B (apoB)-containing lipoprotein (or non-HDL) levels and their production rates. We found that hepatic ablation of PLTP leads to a significant decrease in plasma PLTP activity, HDL lipids, non-HDL lipids, apoAI, and apoB levels. In addition, nuclear magnetic resonance examination of lipoproteins showed that the deficiency decreases HDL and apoB-containing lipoprotein particle numbers, as well as very low-density lipoprotein particle size, which was confirmed by electron microscopy. Moreover, HDL particles from the deficient mice are lipidpoor ones. To unravel the mechanism, we evaluated the apoB and triglyceride production rates. We found that hepatic PLTP deficiency significantly decreases apoB and triglyceride secretion rates. To investigate the role of liver PLTP on HDL production, we set up primary hepatocyte culture studies and found that the PLTP-deficient hepatocytes produce less nascent HDL. Furthermore, we found that exogenous PLTP promotes nascent HDL production through an ATP-binding cassette A 1-mediated pathway. Conclusions-Liver-specific PLTP deficiency significantly reduces plasma HDL and apoB-containing lipoprotein levels. Reduction of production rates of both particles is one of the mechanisms.
P hospholipid transfer protein (PLTP) belongs to a family of lipid transfer/lipopolysaccharide-binding proteins, including cholesteryl ester transfer protein, lipopolysaccharide-binding protein, and bactericidal/permeability increasing protein. 1 It is a monomeric protein of 81 kDa. 2 Besides transferring phosphatidylcholine, PLTP also efficiently transfers sphingomyelin, cholesterol, diacylglycerol, α-tocopherol, cerebroside, and lipopolysaccharide. 3, 4 Although cholesteryl ester transfer protein can also transfer phospholipids, there is no redundancy in the functions of PLTP and cholesteryl ester transfer protein. 5 The liver 2, 6 and small intestine 7 are 2 important sites of PLTP expression.
In human studies, PLTP activity is inversely associated with high-density lipoprotein (HDL) levels. 8, 9 PLTP mediates HDL remodeling and enlargement. 10, 11 PLTP knockout (KO) mice demonstrated a complete loss of phospholipid transfer activities. 3 The deficient mice showed a marked decrease in HDL cholesterol and apolipoprotein AI (apoAI) levels. 3 PLTP transgenic mice showed a 2.5-to 4.5-fold increase in PLTP activity in plasma compared with controls. This resulted in a 30% to 40% reduction of plasma HDL cholesterol levels. 12 Overall, PLTP overexpression or deficiency causes a significant reduction of HDL levels in the circulation, and we still do not have a good explanation for that.
Oram et al 13 reported that exogenous PLTP can promote removing cholesterol and phospholipids from cells by the ATPbinding cassette A 1 (ABCA1) pathway. In contrast, PLTP had no effect on lipid efflux from fibroblasts isolated from a patient with Tangier disease, 14 an HDL deficiency syndrome caused by mutations in ABCA1. The same group of researchers also indicated that an amphipathic helical region (aa144-aa163) of PLTP is critical for ABCA1-dependent cholesterol efflux. 15 We have unexpectedly found that PLTP deficiency causes a significant impairment in hepatic secretion of apoB-containing lipoprotein (BLp). 16 Likewise, it has been reported that animals overexpressing PLTP exhibit hepatic very low-density lipoprotein (VLDL) overproduction. 17 Associations of plasma PLTP activity with elevated apoB levels have been found in humans as well. 18 Dr Largrost's group 19 found that human PLTP transgenic rabbits showed a significant increase of BLp cholesterol in the circulation. Nevertheless, the surprising finding that PLTP affects BLp secretion from the liver has remained unexplained. We believe that PLTP activity is involved in promoting BLp lipidation because PLTP activity and triglyceride enrichment are 2 factors for PLTP-mediated HDL enlargement, 10,11 a process similar to the second step of BLp lipidation. 20 To address the impact of liver-expressed PLTP on lipoprotein metabolism, we created a mouse model that expresses PLTP acutely and specifically in the liver on a PLTP-null background. We found that liver PLTP expression dramatically increases plasma non-HDL cholesterol, non-HDL phospholipid, and triglyceride levels, with a slight increase on plasma HDL lipids, compared with the controls. 21 To further investigate the impact of liver PLTP on nascent HDL and BLp production, we prepared a liver-specific PLTP gene KO mouse model. We found that liver-specific PLTP deficiency significantly reduces both HDL and non-HDL levels. We also explored the possible mechanisms.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Liver PLTP Deficiency Decreases Plasma PLTP Activity
We prepared homozygous PLTP-Flox mice with a C57BL/6 genetic background. However, the Flox mice have no PLTP activity in the circulation because of Neo cassette insertion in intron 3. 21 Because the Neo cassette is double-flanked by both LoxP and flippase recognition target sequences ( Figure 1A ), we crossed our PLTP-Flox mice with flippase-transgenic mice. Flippase recognizes the flippase recognition target sequences. 22 Through this method, we prepared the PLTP-Flox/flippase transgenic (ΔNeo) mice. We found that the ΔNeo mice have normal plasma PLTP activity ( Figure 1B ), as well as plasma cholesterol and phospholipid levels ( Figure IA and IB in the online-only Data Supplement).
Next, we took the advantage of the Cre/LoxP system to delete PLTP exons 2 and 3, which are flanked with LoxP sequences. We injected adenovirus-associated virus (AAV)-Cre and AAV-LacZ (controls) into the ΔNeo mice. Because Cre expression was driven by the liver-specific thyroxine binding globulin promoter, 23 the PLTP deletion occurred specifically in the liver ( Figure 1C ). Moreover, AAV-Cremediated hepatic PLTP ablation resulted in ≈25% reduction of plasma PLTP activity in comparison with the AAV-LacZ controls ( Figure 1D ), indicating that liver-expressed PLTP makes a significant contribution to the PLTP activity in the blood. Furthermore, PLTP activity in AAV-Cre-injected livers is significantly lower than that of controls ( Figure 1E ).
PLTP Hepatic Deficiency Significantly Decreases Both Plasma HDL and Non-HDL Lipid Levels
AAV-Cre-treated PLTP-Flox female animals significantly decreased plasma levels of cholesterol (21%; P<0.01), phospholipids (22%; P<0.05), and triglyceride (32%; P<0.05), as compared with AAV-LacZ control group (Table 1) . We also measured lipid levels in HDL and non-HDL fractions. Our data showed that liver PLTP depletion significantly decreases not only HDL cholesterol (20%; P<0.05) and HDL phospholipid (17%; P<0.05) but also non-HDL cholesterol (29%; P<0.01) and phospholipid (35%; P<0.01) levels ( Table 1) .
Plasma lipid distributions were also examined by fast protein liquid chromatography using pooled plasma. We observed that plasma cholesterol levels are decreased in HDL and non-HDL fractions from the female-deficient mice, as compared with controls ( Figure 2A ). This is also true for total phospholipid distribution ( Figure 2B ) and that of triglyceride ( Figure 2C ). The same phenomena were also observed in AAV-Cre-treated ΔNeo male mice, as compared with male controls ( Figure  IIA -IIC in the online-only Data Supplement).
Next, we assessed plasma apolipoprotein levels by reducing SDS-PAGE and found that the PLTP-deficient mice have a marked decrease of total apoB (60%; P<0.01; Figure 2D ) and apoAI (35%; P<0.01; Figure 2E ), as compared with the control group. This suggests that PLTP deficiency in the liver has impact on both apoAI-containing lipoprotein (HDL) and BLp (non-HDL) levels.
To investigate the mechanisms responsible for the reduced triglyceride and apoB levels in liver-specific PLTP-deficient mouse plasma, we examined the VLDL production rates in vivo. Both AAV-Cre and AAV-LacZ mice were simultaneously injected with [ 35 S]-methionine to label apoB, [ 14 C]-oleic acid to label triglyceride, and poloxamer 407 to block the clearance of VLDL from the circulation. We collected plasma 120 minutes after injection and isolated plasma VLDL by ultracentrifugation (density, 1.006 g/mL). We found that both [ 35 S]-apoB and [ 14 C]-triglyceride levels were significantly decreased in the VLDL from the deficient mice, as compared with that of the controls ( Figure 2F and 2G). This suggests that liver PLTP deficiency prevents VLDL secretion.
To further investigate the effect of hepatic PLTP on lipoprotein metabolism, we used nuclear magnetic resonance to measure total particle number, size, and lipid composition of VLDL, LDL, and HDL. We found that the lack of PLTP in the liver decreases the size and particle number of VLDL particles ( Table 2 ). In addition, these particles have less triglyceride in comparison with controls ( Table 2 ). In LDL and HDL, the reduction in particle numbers was also observed; however, we did not detect any noticeable size differences between the deficient animals and controls (Table 2) . Moreover, HDL from the deficient animals has less cholesterol compared with controls ( Table 2 ). To confirm the HDL results, we isolated HDL from the deficient and control mouse plasma by ultracentrifugation. We measured cholesterol and phospholipid levels in the HDLs and found that, indeed, the HDL particles from the deficient mice is lipid-poor ones ( Table 1) .
We next sought to examine lipoprotein particles under electron microscopy. As shown in Figure 3 , the deficient mice have smaller VLDL particles. After counting 100 particles, the average sizes for VLDL are 52±10 and 37±5 nm (controls versus KO; P<0.05). However, for LDL and HDL particles, there is no significant size difference between the 2 groups ( Figure 3 ). These results confirmed what we have observed in nuclear magnetic resonance analysis ( Table 2 ).
PLTP Promotes Nascent HDL Production
To further investigate the mechanisms behind the reduction of apoAI and HDL lipids in plasma, we examined apoAI production. Both AAV-Cre and AAV-LacZ mice were simultaneously injected with [ 35 S]-methionine to label proteins. We collected plasma and isolated HDL by ultracentrifugation (density, 1.21g/mL). We then separated [ 35 S]-apoAI on SDS-PAGE and found that there is no significant change in [ 35 S]-apoAI levels between the 2 groups ( Figure IIIA and IIIB in the online-only Data Supplement). We also examined ABCA1 and SR-BI levels in liver homogenates and found no significant change either ( Figure IIIC -IIIE in the online-only Data Supplement).
We next sought to measure nascent HDL production directly. Primary hepatocytes from PLTP KO and control mice were isolated and labeled with 3 H-cholesterol. The cells were then incubated with 50 µg/mL human apoAI. The medium was collected after 5-hour incubation. Non-HDL and HDL were separated by ultracentrifugation. The radioactivity in HDL fraction was determined by liquid scintillation counting. We found that PLTP deficiency significantly reduces hepatocyte nascent HDL production ( Figure 4A ).
We further isolated primary hepatocytes from PLTP KO mice and labeled them with 3 H-cholesterol. The cells were then incubated with 50 µg/mL human apoAI together with active recombinant PLTP (rPLTP; 1 μg/mL) or heat-inactivated rPLTP. The medium was collected, and non-HDL and HDL were separated. The radioactivity in HDL fraction was determined by liquid scintillation counting. We found that exogenous active rPLTP significantly promoted hepatocyte nascent HDL production ( Figure 4B ).
It has been reported that exogenous PLTP can promote removing cholesterol and phospholipids from macrophages through the ABCA1 pathway. 13 Although PLTP has no effect on lipid efflux from fibroblasts isolated from ABCA1-deficient patients, 14 hepatocytes may react differently. To evaluate whether PLTP-mediated nascent HDL production is ABCA1 dependent or not, we next isolated primary hepatocytes from liver-specific ABCA1 KO mice ( Figure IVA in the online-only Data Supplement) and labeled them with 3 H-cholesterol. We then incubated them with apoAI together with active rPLTP or inactive rPLTP. We did not find significant difference in nascent HDL production ( Figure IVB Supplement), indicating that indeed rPLTP promotes nascent HDL production from hepatocytes through ABCA1 pathway.
Finally, we performed cross-linking experiment as described in Materials and Methods in the online-only Data Supplement to prove that there is an interaction between PLTP and ABCA1. After protein blotting, we found that there are 2 detectable ABCA1 and PLTP bands, 1 with 260 kDa (complex 1) and 1 with >500 kDa (complex 2; Figure 4C ), indicating that rPLTP and ABCA1 are close enough to be cross-linked and suggesting that PLTP can interact with ABCA1, thus promoting nascent HDL formation.
Discussion
AAV-Cre/Loxp, 24 adenovirus-Cre/Loxp, 25 Mx1-Cre/Loxp (Cre transgene is controlled by the interferon-inducible Mx1 promoter), 26 and albumin-Cre/Loxp (Cre transgene expression is controlled by liver -specific albumin promoter) 27 are 4 approaches for liver-specific gene KO mouse preparation. The former 3 approaches eliminate the gene in the adult mice, whereas the latter eliminates the gene in the early stage of the life. As a pilot study of a drug intervention, AAV-Cre, adenovirus-Cre, and Mx1-Cre approaches are better than albumin-Cre approach because they mimic drug intervention. PLTP is a potential drug target and we chose to block its activity in the adult mice.
There are also some important differences among AAV-Cre, adenovirus-Cre, and Mx1-Cre approaches. The concern 0 0.1 of adenovirus-Cre approach is that the virus can mediate immune response. Mx1-Cre approach may deplete the gene not only in the liver but also in the intestine, at least partially. We chose AAV-Cre approach for the current study because (1) AAV delivers therapeutic transgenes without inducing toxicity, inflammation, or disease in animals and humans 24,28,29 ; (2) the Cre recombinase expression was driven by the liverspecific thyroxine binding globulin promoter 23 ; and (3) the AAV approach resulted in sustained Cre expression in the liver for ≥20 weeks. 24 It is already known that systematic PLTP-deficient mice have less BLp and HDL, compared with the wild-type controls. 16, 30 Nevertheless, the mechanism of PLTP involvement in BLp production and HDL maintenance is still not quite clear. In our current study, we demonstrated that liver-specific PLTP deficiency leads to (1) reduction of PLTP activity in the circulation; (2) reduction of HDL cholesterol and phospholipids, as well as apoAI protein levels; (3) decrease of non-HDL cholesterol, phospholipids, and triglyceride, as well as total apoB levels; (4) decrease of VLDL production rate accompanied by reduction in VLDL particle size and numbers; and (5) reduction of hepatocyte nascent HDL production.
From this study together with previous studies, 17, 21 we could clearly dissect out the contribution of the liver to the total PLTP activity in circulation. Previously, we reported that liver-specific PLTP-expressed mice with a PLTP-null background have 70% to 75% less plasma PLTP activity than that of wild-type mice, indicating that mouse liver makes a small but significant contribution to the plasma PLTP activity. 21 In the current study, we showed that liver-specific PLTP-deficient mice have ≈25% less plasma PLTP activity compared with the controls. In other words, extrahepatic tissues, such as adipose tissue, small intestine, and the lung, 6 make major contributions to plasma PLTP activity.
Liver PLTP deficiency prevents BLp production. Liver is one of the major tissues for lipoprotein production and PLTP expression. Our previous work showed that liver PLTP expression with a PLTP-null background dramatically promotes BLp production, through more lipidation and secretion. 21 Our finding together with previous findings 17, 19 provides the concept that PLTP-mediated VLDL production per se is one of the driving forces for plasma lipoprotein metabolism. In this context, our liver-specific PLTP-deficient mouse is another useful tool to further elucidate the effect of PLTP on VLDL production in the liver. We found that hepatic PLTP deficiency significantly decreases plasma non-HDL lipid levels (Table 1) and BLp production rates ( Figure 2F and 2G ). This may be related to (1) less apoB particle lipidation and secretion 21 and (2) intracellular reactive oxygen species-triggered apoB postendoplasmic reticulum presecretory proteolysis. 30 Our previous study also showed that liver PLTP expression with a PLTP-null background has marginal effect on HDL lipid and apoAI levels. 21 However, in the current study, we found that liver PLTP deficiency (or extrahepatic PLTP expression) decreases HDL lipid and apoAI levels ( Table 1 ; Figure 2E ). This cannot be simply explained by the reduction of plasma PLTP activity (≈25%; Figure 1D ) because heterozygous systemic PLTP deficiency (45% reduction of plasma PLTP activity) has no observable HDL lipid phenotypes. 3 It is possible that there are multiple PLTP pools which have different types of impact on HDL metabolism.
Liver PLTP deficiency-mediated reduction of HDL levels may be related to lower HDL production from the liver. Nascent HDL was found in mesenteric lymph and hepatic perfusates, where it may arise as a result of PLTP-mediated lipid transfer from cellular plasma membrane into the small intestine-secreted and liver-secreted apoAI. [31] [32] [33] ABCA1 mediates the rate-controlling step in HDL particle formation by promoting the efflux of cholesterol and phospholipids to apoAI. 34, 35 Overexpression of hepatic ABCA1 raises HDL cholesterol levels, 36 and liver-specific deletion of ABCA1 dramatically decreases plasma HDL cholesterol in mice. 27 Oram et al 13 reported that exogenous PLTP can promote removing cholesterol and phospholipids from macrophages by the ABCA1 pathway. In contrast, PLTP had no effect on lipid efflux from fibroblasts isolated from a patient with Tangier disease. 14 The same group of researchers also indicated that an amphipathic helical region (aa144-aa163) of PLTP is critical for ABCA1-dependent cholesterol efflux, 15 and they found that PLTP can stabilize ABCA1 on cell plasma membrane. 13 In line with these reports, we found that liver PLTP is a significant player in nascent HDL production through ABCA1 pathway. On the basis of our observation, ablation of PLTP in the liver has no effect on apoAI production ( Figure IIIA and IIIB in the online-only Data Supplement) and ABCA1 protein levels in tissue homogenates ( Figure IIIC and IIID in the online-only Data Supplement). However, PLTP deficiency significantly reduces nascent HDL production ( Figure 4A) , and exogenous active rPLTP significantly enhances hepatocyte nascent HDL production ( Figure 4B ). Furthermore, we found that this PLTP-mediated effect requires the presence of ABCA1 because rPLTP has no effect in HDL production in ABCA1-deficient primary hepatocytes ( Figure IVA in the online-only Data Supplement). We believe that, as proposed in macrophages, 13 PLTP may function to (1) stabilize liver ABCA1 and (2) shuttle lipids between cells and existing HDL particles (formed first through ABCA1 action).
Hepatic PLTP deficiency-mediated reduction of HDL levels might be related to less VLDL production. PLTP can transfer lipids from the surface of BLp into HDL. 37, 38 Systemic PLTP deficiency completely blocks this transfer activity. 3, 5 After mature BLp secreted into the blood and lipoprotein lipasemediated triglyceride hydrolysis, the core of BLp shrinks, 39 and the redundant surface constituents (sphingomyelin and phosphatidylcholine, as well as free cholesterol) can be the substrates of PLTP, transferring from BLp to HDL.
PLTP may have an antiatherogenic function because it promotes nascent HDL production. However, recent researches challenge the concept that rising of plasma HDL will uniformly translate into reductions in coronary heart diseases. HDL particles are heterogeneous in size and composition. 40 Understanding the origination of HDL and characterization of HDL, all subclasses are as important as its plasma concentration in leading to atherosclerotic lesion development. In this study, we showed that PLTP activity promotes nascent HDL production ( Figure 4A and 4B) , through the interaction between PLTP and ABCA1 ( Figure 4C ). Whether this PLTP function is antiatherogenic or proatherogenic deserves further investigation. However, PLTP overexpression promotes 41, 42 and deficiency prevents 16 atherosclerosis in mice.
Taking together the results from the current study and our previous one, 21 we proposed a model for PLTP-mediated HDL and non-HDL production ( Figure 4D ). We believe that (1) PLTP may be involved in the second step of BLp lipidation, promoting the fusion of primordial BLp and triglyceride/ sphingomyelin/phosphatidylcholine-rich lipid droplets; (2) PLTP may promote ABCA1-mediated nascent HDL production through stabilizing ABCA1 and shuttling lipids between cells and existing HDL particles; and (3) PLTP may transfer BLp surface components into HDL, after lipoprotein lipasemediated core triglyceride hydrolysis. . Nascent high-density lipoprotein (HDL) production in cultured primary hepatocytes. The procedure of nascent HDL production is described in Materials and Methods in the online-only Data Supplement. A, Nascent HDL production in phospholipid transfer protein (PLTP) knockout (KO) and wild-type (WT) primary hepatocytes (no exogenous PLTP treatment). B, Nascent HDL production in PLTP KO primary hepatocytes with either active recombinant (rPLTP) or heart inactive (HI) rPLTP treatment. C, Cross-linking between rPLTP and ABCA1. The procedure is described in Materials and Methods in the online-only Data Supplement (*P<0.05 and **P<0.01). D, A model of PLTP-mediated lipoprotein production. PLTP is involved in the second step of apolipoprotein B-containing lipoprotein (BLp) lipidation in endoplasmic reticulum lumen, where the primordial BLp is fused with triglyceride (TG)/sphingomyelin (SM)/phosphatidylcholine (PC)-rich lipid droplet. PLTP also can promote ABCA1-mediated nascent HDL production through stabilizing ABCA1. Finally, PLTP can transfer BLp surface lipids into HDL in the circulation. WB indicates Western blot. 
